Company: ATRA
Filing Date: 2025-03-07
Form Type: 10-K
Source: 0000950170-25-035507
Chunk: 171

Company: Atara Biotherapeutics, Inc.
Filing Date: 2025-03-07
Form: 10-K
Item: Item 1B
Chunk 171
---
 other preclinical product candidates; and

•leveraging our relationships and experience to in-license or acquire additional product candidates or technologies. 

In addition, we believe it is important to invest in the development of new product candidates to continue to build the value of our product candidate pipeline and our business. We plan to continue to advance our most promising early product candidates into 

86

preclinical development with the objective of advancing these early-stage programs to human clinical studies over the next several years. 

Our expenditures on current and future preclinical and clinical development programs are subject to numerous uncertainties in timing and cost to completion. The duration, costs, and timing of clinical studies and development of our product candidates will depend on a variety of factors, including: 

•the availability of qualified drug supply for use in our ongoing Phase 3 or other clinical studies;

•the scope, rate of progress, and expenses of our ongoing clinical studies, potential additional clinical studies and other research and development activities; 

•the potential review or reanalysis of our clinical study results;

•future clinical study results; 

•uncertainties in clinical study enrollment rates or discontinuation rates of patients; 

•potential additional safety monitoring or other studies requested by regulatory agencies; 

•changing medical practice patterns related to the indications we are investigating;

•significant and changing government regulation;

•disruptions caused by man-made or natural disasters or public health pandemics or epidemics, including, for example, the COVID-19 pandemic; and 

•the timing and receipt of any regulatory approvals, as well as potential post-market requirements. 

The process of conducting the necessary clinical research to obtain approval from the FDA and other regulators is costly and time consuming and the successful development of our product candidates is highly uncertain. The risks and uncertainties associated with our research and development projects are discussed more fully in the section of this report titled “1A. Risk Factors.” As a result of these risks and uncertainties, we are unable to determine with any degree of certainty the duration and completion costs of our research and development projects, or if, when, or to what extent we will generate revenues from the commercialization and sale of any of our product candidates that obtain regulatory approval. 

General and Administrative Expenses 

General and administrative expenses consist primarily of compensation and benefits for legal, human resources, finance and other general and administrative employees, including stock-based compensation; professional services costs, including legal, patent, human resources, audit and accounting services; other outside services and consulting costs; and information technology and overhead expenses. 

Interest Income